239 related articles for article (PubMed ID: 31867105)
1. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia.
Nasiri AR; Rodrigues MR; Li Z; Leitner BP; Perry RJ
Cancer Metab; 2019; 7():10. PubMed ID: 31867105
[TBL] [Abstract][Full Text] [Related]
2. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer.
Wang Y; Nasiri AR; Damsky WE; Perry CJ; Zhang XM; Rabin-Court A; Pollak MN; Shulman GI; Perry RJ
Cell Rep; 2018 Jul; 24(1):47-55. PubMed ID: 29972790
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin restores insulin and growth hormone secretion in obese mice.
Huang Z; Huang L; Wang C; Zhu S; Qi X; Chen Y; Zhang Y; Cowley MA; Veldhuis JD; Chen C
J Endocrinol; 2020 Apr; 245(1):1-12. PubMed ID: 31977312
[TBL] [Abstract][Full Text] [Related]
4. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
Okada J; Yamada E; Saito T; Yokoo H; Osaki A; Shimoda Y; Ozawa A; Nakajima Y; Pessin JE; Okada S; Yamada M
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979355
[TBL] [Abstract][Full Text] [Related]
8. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.
Kim Y; Babu AR
Diabetes Metab Syndr Obes; 2012; 5():313-27. PubMed ID: 22977310
[TBL] [Abstract][Full Text] [Related]
9. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
10. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Schech A; Yu S; Goloubeva O; McLenithan J; Sabnis G
Endocr Relat Cancer; 2015 Aug; 22(4):645-56. PubMed ID: 26113604
[TBL] [Abstract][Full Text] [Related]
11. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
14. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Tanday N; Irwin N; Flatt PR; Moffett RC
Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
[TBL] [Abstract][Full Text] [Related]
16. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
[TBL] [Abstract][Full Text] [Related]
17. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Baretić M; Troskot R
Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
[TBL] [Abstract][Full Text] [Related]
18. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
Devenny JJ; Godonis HE; Harvey SJ; Rooney S; Cullen MJ; Pelleymounter MA
Obesity (Silver Spring); 2012 Aug; 20(8):1645-52. PubMed ID: 22402735
[TBL] [Abstract][Full Text] [Related]
19. Effect of dapagliflozin on colon cancer cell [Rapid Communication].
Saito T; Okada S; Yamada E; Shimoda Y; Osaki A; Tagaya Y; Shibusawa R; Okada J; Yamada M
Endocr J; 2015; 62(12):1133-7. PubMed ID: 26522271
[TBL] [Abstract][Full Text] [Related]
20. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
